Faculty profile

Christopher Power

ResearcherMedicine/NeurologyUniversity of Alberta

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses may be missing. Find their university profile.

Christopher Power

Researcher

Medicine/Neurology

Health Sciences

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
30 publications in the last five years, latest in 2026.
Senior (last) author on 12 recent papers, a sign of leading a research group.
Principal investigator on 16 research grants (16 CIHR), most recently in 2024.
Supervised 3 trainees who won CIHR awards, most recently in 2013.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

143

Publications

149

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Inflammation Hiv/Aids Hiv Multiple Sclerosis Biomarkers Animal Models Nervous System Therapeutics

Latest papers

Targeted Degradation of Histone Deacetylase 8 Using Proteolysis Targeting Chimeras Technology: A Promising Approach for Glioblastoma Treatment.
Drug design, development and therapy · 2026
Hexavalent Chromium Induces Apoptosis and Autophagy in Human Neurons and Astrocytes via MAPK Pathway Activation.
Biological trace element research · 2026
Brain and neural cell type proteomics reveal extracellular matrix proteins enriched in progressive multiple sclerosis.
Nature communications · 2026

All 143 publications

Latest funding

Precision health IDEAS (Inclusion/Diversity/Equity/Accessibility/Sustainability) for NeuroHIV: disrupted immunometabolism in the brain
CIHR · 2024 · Nominated PI
$20,000
Understanding inflammation in the brain: integration of glycomics and viruses in multiple sclerosis
SSHRC · 2022 · Co-investigator
$125,000
Pyroptosis in the CNS: Molecular mechanisms & therapeutic targets in progressive MS
CIHR · 2021 · Nominated PI
$1,032,750

All 25 grants and awards

143 publications.

Targeted Degradation of Histone Deacetylase 8 Using Proteolysis Targeting Chimeras Technology: A Promising Approach for Glioblastoma Treatment.

Chotitumnavee J, Seemaung P, Settacomkul R, Sukprasert R, Itoh Y, Suzuki T, Srihirun S, Power C, Vivithanaporn P

Drug design, development and therapy2026

DOI: 10.2147/dddt.s555228 PMID: 41878673

Hexavalent Chromium Induces Apoptosis and Autophagy in Human Neurons and Astrocytes via MAPK Pathway Activation.

Phuagkhaopong S, Sukprasert R, Settacomkul R, Ospondpant D, Suknuntha K, Khemawoot P, Power C, Vivithanaporn P

Biological trace element research2026

DOI: 10.1007/s12011-026-05046-0 PMID: 41936018

Brain and neural cell type proteomics reveal extracellular matrix proteins enriched in progressive multiple sclerosis.

Wang H, Pollock NM, Miranzadeh Mahabadi H, Patel J, Moussa EW, Fernandes JP, Branton WG, Zhang N, Elliott C, Schmitt L, Power C, Julien O

Nature communications2026

DOI: 10.1038/s41467-025-68118-0 PMID: 41501060

Neurological complications of Orthopoxvirus infections: neurotropism and neurovirulence.

Miranzadeh Mahabadi H, Noyce RS, Evans DH, Power C

Brain : a journal of neurology2025Senior author

DOI: 10.1093/brain/awaf181 PMID: 40372132

Immunometabolism perturbations in post-COVID-19 condition: interleukin-6 and monoamine oxidase interactions drive neuropsychiatric syndromes.

Ogando NS, Elaish M, Mahabadi HM, Langdon KD, Das SK, Joseph JT, Fujiwara E, Holt A, Kaur K, Branton W, Gheblawi M, Lacy P, Oudit GY, Hobman TC, Lam GY, Power C

Brain, behavior, and immunity2025Senior author

DOI: 10.1016/j.bbi.2025.07.002 PMID: 40619111

Peroxisomes as emerging clinical targets in neuroinflammatory diseases.

Roczkowsky A, Rachubinski RA, Hobman TC, Power C

Frontiers in molecular neuroscience2025Senior author

DOI: 10.3389/fnmol.2025.1642590 PMID: 40949164

Pegivirus-Associated Encephalomyelitis in Immunosuppressed Patients.

Scheibe F, Melchert J, Radbruch H, Siebert E, Best TD, Kohler S, Fitzek M, Kowski A, Siffrin V, Meinhardt J, Raspe R, Horst V, Zukunft B, Budde K, van Landeghem FKH, Power C, Eckardt KU, Endres M, Drosten C, Corman VM, Ruprecht K

The New England journal of medicine2025

DOI: 10.1056/nejmc2501512 PMID: 40334164

Brain RNA profiling highlights multiple disease pathways in persons with HIV-associated neurocognitive disorder.

Branton WG, Zhang N, Cohen EA, Brew BJ, Gill MJ, Gelman BB, Kong L, Power C

AIDS (London, England)2025Senior author

DOI: 10.1097/qad.0000000000004116 PMID: 39820157

A secondary metabolite of Limosilactobacillusreuteri R2lc drives strain-specific pathology in a spontaneous mouse model of multiple sclerosis.

Archer D, Pérez-Muñoz ME, Tollenaar S, Veniamin S, Hotte N, Cheng CC, Nieves K, Oh JH, Morceli L, Muncner S, Barreda DR, Krishnamoorthy G, Power C, van Pijkeren JP, Walter J

Cell reports2025

DOI: 10.1016/j.celrep.2025.115321 PMID: 39985770

Anti-inflammatory effects of moxifloxacin and levofloxacin on cadmium-activated human astrocytes: Inhibition of proinflammatory cytokine release, TLR4/STAT3, and ERK/NF-κB signaling pathway.

Phuagkhaopong S, Sukwattanasombat J, Suknuntha K, Power C, Wonganan P, Vivithanaporn P

PloS one2025

DOI: 10.1371/journal.pone.0317281 PMID: 39808652

Precision health IDEAS (Inclusion/Diversity/Equity/Accessibility/Sustainability) for NeuroHIV: disrupted immunometabolism in the brain

Nominated PICIHR2024T. Gr.: Embracing Diversity -HIV/AIDS/STBBI-Co-infections and Co-morbidities-LOI

Principal investigators: Power, Christopher; Lang, Raynell

Keywords: Animal Models; Biomarkers; Cell Cultures; Genomics; Hiv; Nervous System; Neuropsychiatric Disorders; Precision Health; Proteomcs; Therapeutics

$20,000

Understanding inflammation in the brain: integration of glycomics and viruses in multiple sclerosis

Co-investigatorSSHRC2022New Frontiers in Research Fund - Exploration

Principal investigators: Plemel, Jason

Keywords: Multiple sclerosis; Virology; Glycomics; Clinical samples; animal models; single cell transcriptomics; machine learning; molecular arrays

$125,000

Pyroptosis in the CNS: Molecular mechanisms & therapeutic targets in progressive MS

Nominated PICIHR2021Project Grant

Principal investigators: Power, Christopher

Keywords: Multiple Sclerosis; Neuroinflammation; Pet Imaging; Pyroptosis; Regulated Cell Death; Therapeutics

$1,032,750

Deciphering the impact of aging and inflammation on neurocognitive impairments in people with Post-Acute Sequelae of COVID-19 (PASC)

Nominated PICIHR2021Op. Gr.: Addr. the Wider Impacts of COVID- Exacerb. of disp. among marg. pops.

Principal investigators: Power, Christopher

Keywords: Inflammation

$498,020

The University of Alberta Multiple Sclerosis Center Research Symposium- Remyelination and Repair in MS: From Bench to Bedside

Co-investigatorCIHR2019Planning and Dissemination Grant - Institute Community Support

Principal investigators: Kerr, Bradley

Keywords: Axon; Microglia; Minocycline; Multiple Sclerosis; Myelin; Oligodendrocyte; T-Cells

$10,000

Lentivirus persistence in the brain: viral, host and therapeutic determinants

Nominated PICIHR2019Project Grant

Principal investigators: Power, Christopher

Keywords: Aging; Animal Models; Antiretroviral Therapies; Hiv; Nervous System; Neuroinflammation; Sex

$1,149,414

Canadian HIV-Ageing Multidisciplinary Programmatic Strategy (CHAMPS) in NeuroHIV

Nominated PICIHR2018Team Grant - HIV/AIDS Comorbidities Prevention and Healthy Living

Principal investigators: Power, Christopher; Fujiwara, Esther

Keywords: Ageing; Hiv; Inflammation; Micrornas; Myeloid Cells; Neurocognitive Impairments; Neuropathic Pain; Peroxisomes; Proteases; Sex And Gender

$2,500,000

University of Alberta Multiple Sclerosis Centre Research Symposium- Multiple Sclerosis and Stem Cells: Biology and Applications

Nominated PICIHR2017Planning and Dissemination Grant - Institute Community Support

Principal investigators: Power, Christopher

Keywords: Clinical Trials; Ethics; Immunology; Inflammation; Multiple Sclerosis; Stem Cells; Symposium; Therapy

$10,000

Canadian NeuroAIDS Research Team (CNART): interactions with aging and co-infections

Nominated PICIHR2017Team Grant: HIV/AIDS Comorbidities Prevention and Healthy Living - LOI

Principal investigators: Power, Christopher; Fujiwara, Esther

Keywords: Aging; Biomarker; Ethnic Diversity; Hepatitis C Virus; Hiv/Aids; Neuroaids; Neurocognitive Impairment; Neuropathic Pain; Sex And Gender Diversity; Syphillis

$25,000

Therapeutic effects of intranasal insulin on HIV-associated neurocognitive disorder

Nominated PICIHR2016Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research

Principal investigators: Power, Christopher; Gill, Michael J

Keywords: Biomarkers; Clinical Trial; Hiv-Associated Neurocognitive Disorder; Hiv/Aids; Intranasal Insulin

$234,375

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Christopher Power

Research

Latest papers

Latest funding

Targeted Degradation of Histone Deacetylase 8 Using Proteolysis Targeting Chimeras Technology: A Promising Approach for Glioblastoma Treatment.

Hexavalent Chromium Induces Apoptosis and Autophagy in Human Neurons and Astrocytes via MAPK Pathway Activation.

Brain and neural cell type proteomics reveal extracellular matrix proteins enriched in progressive multiple sclerosis.

Neurological complications of Orthopoxvirus infections: neurotropism and neurovirulence.

Immunometabolism perturbations in post-COVID-19 condition: interleukin-6 and monoamine oxidase interactions drive neuropsychiatric syndromes.

Peroxisomes as emerging clinical targets in neuroinflammatory diseases.

Pegivirus-Associated Encephalomyelitis in Immunosuppressed Patients.

Brain RNA profiling highlights multiple disease pathways in persons with HIV-associated neurocognitive disorder.

A secondary metabolite of Limosilactobacillusreuteri R2lc drives strain-specific pathology in a spontaneous mouse model of multiple sclerosis.

Anti-inflammatory effects of moxifloxacin and levofloxacin on cadmium-activated human astrocytes: Inhibition of proinflammatory cytokine release, TLR4/STAT3, and ERK/NF-&#x3ba;B signaling pathway.

Understanding inflammation in the brain: integration of glycomics and viruses in multiple sclerosis

Frequent collaborators

Christopher Power

Esther Fujiwara

Fabrizio Giuliani

Douglas Zochodne

Nicolas Chomont

Jean-Pierre Routy

Jean-Pierre Routy

Nicolas Chomont

Frank Wuest

Petronela Ancuta

Andrew Mason

Marek Michalak

Thomas Simmen

Guido van Marle

Jérôme Estaquier

Jack Jhamandas

Mohammad-Ali Jenabian

Bradley Kerr

Mohammad-Ali Jenabian

Deirdre Church

Francesca Di Cara

Michael Surette

Crystal Fong

Suresh Menon

David Evans

Paul Beck

David Westaway

Babita Agrawal

Jian-Qiang Lu

Tom Hobman

Anti-inflammatory effects of moxifloxacin and levofloxacin on cadmium-activated human astrocytes: Inhibition of proinflammatory cytokine release, TLR4/STAT3, and ERK/NF-κB signaling pathway.